Patient-Derived Orthotopic Xenograft (PDOX) Models

Patient-derived orthotopic xenograft models combine two sources of fidelity: patient tumor tissue engrafted without an intervening culture step, and implantation at the anatomically matched primary site. The model retains donor histology, genomic architecture, and intratumoral heterogeneity, and places that tissue in the stromal and vascular context in which the disease originally arose.

This is the configuration appropriate for invasion and metastasis research in patient-derived material. Subcutaneous implantation places human tumor tissue in a biological context that diverges substantially from the native organ: extracellular matrix composition, vascular architecture, oxygen tension, resident stromal populations, and paracrine signaling in the dorsal subcutaneous space have little in common with breast, pancreas, peritoneum, colon, or lung. Restoring the organ-specific environment supports spontaneous dissemination along clinically relevant routes, which subcutaneous patient-derived models do not reliably produce.

Altogen Labs performs orthotopic implantation across multiple indications in an IACUC-regulated facility, with surgical technique, analgesia, and postoperative monitoring defined per site. To discuss feasibility for a specific indication, request a quote.

Tissue handling

PDOX inherits the handling constraints of all patient-derived work. Tissue is transported in cold buffered medium and processed promptly, since prolonged warm ischemia and extended intervals outside the body progressively reduce engraftment efficiency. Material is prepared as intact fragments rather than dissociated, because orthotopic implantation of fragments better reproduces the invasive front, which is frequently the feature of interest. Institutional review board approval and written informed consent are mandatory.

Site-specific configurations

Mammary fat pad implantation for breast tumors reconstitutes the mammary stromal environment and supports dissemination to lung and lymph node. Published comparisons indicate that orthotopic implantation achieves both better engraftment and faster growth than subcutaneous implantation of the same patient material in this indication.

Cecal or colonic wall implantation for colorectal tumors recapitulates local invasion through the bowel wall and subsequent liver metastasis, reproducing the dominant pattern of clinical progression. Intraperitoneal delivery for ovarian tumors reproduces the peritoneal dissemination and ascites formation characteristic of high grade serous disease, a pattern subcutaneous models cannot generate. Pancreatic implantation reproduces the desmoplastic stromal reaction and early local invasion that define pancreatic ductal adenocarcinoma and that substantially influence drug penetration. Intracranial implantation places tumor behind the blood-brain barrier, which is a prerequisite for any meaningful assessment of central nervous system exposure.

Monitoring and endpoints

Orthotopic sites are not accessible to caliper measurement, so longitudinal assessment requires an imaging strategy established at design stage rather than improvised later. Where the donor material can be transduced with a reporter, bioluminescent imaging permits repeated non-invasive measurement in the same animal, which reduces cohort size and removes the variance introduced by terminal sampling across multiple timepoints. Where transduction is not possible, the study is designed around staged terminal cohorts, survival endpoints, and terminal tumor weight.

Endpoints commonly include primary tumor burden, incidence and organ distribution of metastasis, survival, and histopathological assessment of the invasive front. Immunohistochemistry, molecular endpoints, and tissue collection are integrated as the protocol requires.

Applied examples

Pancreatic drug penetration. A patient-derived pancreatic tumor is implanted into the pancreas, and a candidate agent is assessed for antitumor effect alongside histological assessment of stromal density, addressing whether limited activity reflects intrinsic resistance or failure to penetrate the desmoplastic stroma.

Breast metastasis. A triple negative breast tumor is implanted into the mammary fat pad and treated after the primary tumor is established, with lung and lymph node burden quantified at endpoint to establish whether the agent affects dissemination as well as primary growth.

Ovarian peritoneal disease. Patient-derived ovarian tumor material is delivered intraperitoneally, and treatment effect is assessed against peritoneal tumor burden and ascites volume rather than a single measurable mass.

Passage, documentation, and surgical oversight

Passage history, host background, implantation site, and provenance are recorded in accordance with established minimal information reporting standards for patient-derived xenografts. Formal pharmacology is generally reserved for early passage material, recognizing that stromal replacement and transcriptional drift accumulate across serial passage. All procedures are conducted under active IACUC protocols, with surgical technique, analgesia regimen, postoperative monitoring schedule, and humane endpoints specified before study initiation. GLP standards are applied where a study is formally designated as GLP.

Send indication and tissue details, or request a quote.